Pharmaceuticals Company

Aneira Pharma Inc.

97%

Funding Goal $4,500,000
Funding Raised So Far $4,100,000
Funding Commitments $250,000
Funding Remaining $150,000
Funding Type Common Equity
Pre-Money Valuation
Investor Ownership
Interest / Dividend
Previous Funding

Company Overview

A topical scalp hair/eyebrow growth formulation which are 46.4% more efficacious at growing hair than any other topical hair growth product on the market.

Aneira is a commercial-stage pharmaceutical company with patented topical formulations designed to grow longer, darker, and thicker hair. Key products include ANR-001.1 for scalp hair growth and ANR-002 for eyebrow growth, both products demonstrating superior efficacy to any commercially available topical hair growth products. Both products utilize a combination of latanoprost and minoxidil in a proprietary vehicle designed to enhance penetration and hair growth. Aneira has completed Phase I and Phase IIA clinical trials for both products which proved extremely efficacious and very safe.

Aneira plans to finish Phase II and Phase III clinical trials in Australia by the end of 2026. Aneira will then conduct a Phase III clinical trial in the United States and clinical trials in other regions the world with clinical partners. Both products are now commercially available in the United States by prescription and will go on sale in Brazil and Canada in the second half of 2025. Aneira is pursuing world-wide sales by forging partnerships with pharmaceutical companies all around the world.

Please see the clinical data of both the scalp growth and the eyebrow growth product found in the company pitch deck on on the documents tab.

lock icon

Invest in Company

Sign up or log in now to unlock profile details and access financials, company documents, and invest in companies.

Investor Sign Up
Investor Log In

Business Summary

Company Age
Employees
Sub-Industry
Prior Year Revenue
Current Year Revenue
Next Year Revenue

Products/Services

ANR-001.1 and ANR-002


- ANR-001.1: Once-daily topical scalp treatment combining minoxidil and latanoprost. Clinical trials demonstrated up to 61% increase in hair count and 109% increase in hair width in approximately four months.

- ANR-002: Topical eyebrow enhancement formula also combining minoxidil and latanoprost, clinically proven to achieve up to 50% increased brow density in just 90 days.

- Pipeline Products: ANR-003 (eyebrow growth for chemotherapy patients); ANR-004 (latanoprost + cyclosporine for alopecia areata), ANR-005 (eyelash), and ANR-006 (facial hair) and ANR-001.1B which is a less expensive version of ANR-001.1 which can be sold widely in developing world economies.

Management

John E. Wurst
Managing Director Executive Officer
John E......

John has a background in science and law with a Bachelor of Arts in Biochemistry from University of California San Diego, a Juris Doctor from Creighton University School of Law, a Masters of Law from George Washington University and Masters in Biology from the University of Nebraska. John has spent over twenty-five years in the pharmaceutical business acting in roles such as Patent Counsel and General Counsel. John gained extensive experience in hair growth at Allergan working on products such as LATISSE and Allergan's eyebrow growth and scalp growth programs, which were ultimately discontinued.

Kenton Abel, Ph.D.
Director Advisor
Kenton A......

Dr. Abel has over twenty-five years experience in the pharmaceutical industry and was co-founder of Bonti, which was sold to Allergan for $270 million. Dr. Abel is also the founder of Object Pharma which is making a new form of BOTOX. Dr. Abel is both an attorney and a scientist.

Richard Kalman
Executive Vice President Manufacturing/Production
Richard K......

Proven executive management track record
• >20 years in pharmaceutical/medical device
manufacturing
• Specializing in operations, product development,
supply chain & quality systems

97%

Funding Goal $4,500,000
Funding Raised So Far $4,100,000
Funding Commitments $250,000
Funding Remaining $150,000
Funding Type Common Equity
Pre-Money Valuation
Investor Ownership
Interest / Dividend
Previous Funding

Documents

Contact

Aneira Pharma Inc.

San Diego, CA 92122, US

Top 10 Tips for Entrepreneurs Seeking Funding

Users who follow these tips increase their fundraising odds substantially.

  • Complete Your Funding Profile
    • Complete your funding profile with all sections filled, including your products and services, a complete management team with headshots, and slideshow with product images.
  • Complete a Business Plan (Optional)
    • Complete a Business Plan in EquityNet and refine your financial projections using the benchmarking alerts in the Business Plan Analysis report.
  • Upload Important Investment Documents
    • Upload and present any other important investment documents such as pitch decks, financial statements, and offering materials.
  • Use EquityNet Crowdcast
    • Use the EquityNet Crowdcast system to automatically email invitations to your contacts in order to build additional exposure for your company.
  • Construct Concise Introductory Messages
    • Construct and send a concise introductory message to investors, including primary reasons why they should want to invest such as KPIs, expected returns, and forecasted revenue.
  • Be Proactive in Messaging Investors
    • Be proactive in messaging many investors and include a simple way for them to connect with you for a web meeting or call, such as a Calendly link.
  • Use the Activity System
    • Use the Activity system to track interested investors, and send prompt follow-up messages to investors who viewed your profile or showed interest.
  • Prepare for Due Diligence
    • Prepare for due diligence questions by interested investors and use your Business Plan and investment documents to satisfy such requests.
  • Keep Your Funding Profile Updated
    • Keep your funding profile updated with new funding raised/committed and message interested investors with any new milestones achieved.
  • Do Not Respond to Unknown Investors
    • Do not respond to or engage any parties outside of EquityNet that are not listed as approved investors (this may happen due to your public profile and LinkedIn connections).